

## **AMENDMENTS TO THE SPECIFICATION:**


Please replace the title "Novel Combination" with the following new title:



Pharmaceutical Comprising a PDE 5 Inhibitor and an Angiotensin II Receptor Antagonist  
for the Treatment of Hypertension

Please replace the paragraph beginning at page 6, line 1, with the  
following rewritten paragraphs:


The pyrazolo[4,3-*d*]pyrimidin-7-ones disclosed in ~~EP-A-0463756, EP-A-0526004 and published international patent applications WO 93/06104, WO 98/49166, WO 99/54333, WO 00/24745, WO 00/27848, WO 01/27112, WO 01/98304 and WO 01/27113~~ U.S. Patent Nos. 5,250,534, 5,346,901, 5,719,283, 5,272,147, 5,426,107, 6,743,719, 6,251,904, 6,458,951, 6,333,330, 6,670,366, 5,728,862, 5,998,436, 6,004,938, 6,133,284, 6,156,903, 6,232,306, 6,472,525, 6,573,279, 6,576,761, 6,583,147, 6,756,373, 6,809,200, 6,844,436, 6,420,557 and 6,677,335, and U.S. Patent Application Publication Nos. 2004/180994, 2001/039271, 2002/038024, 2003/176696, 2002/040140 and 2004/152712; the pyrazolo[3,4-*d*]pyrimidin-4-ones disclosed in ~~EP-A-0995750, EP-A-0995751 and published international patent application WO 93/07149~~ U.S. Patent Nos. 6,333,330, 6,670,366, and 6,407,114; the pyrazolo[4,3-*d*]pyrimidines disclosed in ~~published international patent applications WO 01/18004, WO 02/00660 and WO 02/59126~~ U.S. Patent Nos. 6,777,419, and U.S. Patent Application Publication Nos. 2004/029900 and 2004/053945; the quinazolin-4-ones disclosed in ~~published international patent application WO 93/12095~~ U.S. Patent No. 5,482,941; the pyrido[3,2-

~~d]~~pyrimidin-4-ones disclosed in ~~published international patent application WO 94/05661~~  
U.S. Patent No. 5,591,742; the purin-6-ones disclosed in ~~EP-A-1092718 and in published~~  
~~international patent application WO 94/00453~~ U.S. Patent Nos. 5,734,053, 6,440,982,  
6,586,439 and 6,593,332, and U.S. Patent Application Publication Nos. 2003/004173 and  
2003/013727; the hexahydropyrazino[2',1':6,1]pyrido[3,4-*b*]indole-1,4-diones disclosed  
in ~~published international application WO 95/19978~~ U.S. Patent Nos. 6,025,494,  
6,127,542, 6,140,329, 6,143,746, 6,369,059, 6,608,065 and 6,784,179, and U.S. Patent  
Application Publication No. 2002/119976; the imidazo[5,1-*f*][1,2,4]triazin-ones disclosed  
in ~~EP-A-1092719 and in published international application WO 99/24433~~ U.S. Patent  
Nos. 6,503,908, 6,362,178, 6,566,360 and 6,890,922; the bicyclic compounds disclosed  
in ~~published international application WO 93/07124~~ U.S. Patent Nos. 5,576,322,  
5,693,652, and 5,801,180 and the imidazoquinazolinones disclosed in ~~Rotella DP et al; J.~~  
~~Med. Chem. 43(7), 1257-1263, 2000.~~ having any of the following chemical structures






Additional examples of PDE5 inhibitors for use with the invention include compounds that are within the scope of any of the following two general formulas:



wherein R1 is methyl or ethyl; R2 is ethyl or n-propyl; and R3 and R4 are each independently H, or C1-C6 alkyl optionally substituted with C5-C7 cycloalkyl or with morpholino; and pharmaceutically acceptable salts thereof; and



wherein R1 is C1-C6 alkyl; R2 is H, methyl, or ethyl; R3 is C2-C4 alkyl; R4 is C1-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7; C2-C4 alkenyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7; C2-C4 alkanoyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7; or halo; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR8)-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C1-C4 alkyl groups; R7 is H or C1-C4 alkyl; and R8 is H, C1-C3 alkyl or hydroxy C2-C3 alkyl; and pharmaceutically acceptable salts thereof.

Please replace the paragraph beginning at page 6, line 19, with the following rewritten paragraph:

The contents of the ~~published patent applications and journal articles~~  
above cited patents or patent application publications and in particular the general  
formulae of the therapeutically active compounds of the claims and exemplified  
compounds therein are incorporated herein in their entirety by reference thereto.